Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
MGRM 
Monogram Orthopaedics Inc. Common Stock (MGRM)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/12/2025: MGRM (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $8.4
1 Year Target Price $8.4
| 0 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -16.84% | Avg. Invested days 28 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/12/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 233.64M USD | Price to earnings Ratio - | 1Y Target Price 8.4 |
Price to earnings Ratio - | 1Y Target Price 8.4 | ||
Volume (30-day avg) 1 | Beta 0.7 | 52 Weeks Range 1.92 - 6.02 | Updated Date 09/14/2025 |
52 Weeks Range 1.92 - 6.02 | Updated Date 09/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.54 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -72.9% | Return on Equity (TTM) -228.82% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 221102110 | Price to Sales(TTM) 243.53 |
Enterprise Value 221102110 | Price to Sales(TTM) 243.53 | ||
Enterprise Value to Revenue 230.43 | Enterprise Value to EBITDA -5.1 | Shares Outstanding 40632400 | Shares Floating 30581545 |
Shares Outstanding 40632400 | Shares Floating 30581545 | ||
Percent Insiders 54.55 | Percent Institutions 4.97 |
Upturn AI SWOT
Monogram Orthopaedics Inc. Common Stock
Company Overview
History and Background
Monogram Orthopaedics Inc. (MGRM) was founded to develop and commercialize patient-specific orthopedic implants using advanced imaging, 3D printing, and robotics. The company aims to improve surgical outcomes and reduce revision rates in joint replacement.
Core Business Areas
- Robotics and Surgical Planning: Develops and markets robotic surgical systems and associated planning software for precise implant placement.
- Patient-Specific Implants: Designs and manufactures customized orthopedic implants tailored to individual patient anatomy.
- Orthobiologics: Develops and markets biologic materials aimed at improving implant integration and bone healing.
Leadership and Structure
Monogram Orthopaedics is led by its CEO, Dr. Douglas Unis. The company has a board of directors overseeing its strategic direction. The organizational structure includes departments for research and development, manufacturing, sales and marketing, and regulatory affairs.
Top Products and Market Share
Key Offerings
- mBESS Robotic System: A robotic surgical system for total knee arthroplasty. Market share data is currently not available, as the system is still in pre-commercial stage. Competitors include Stryker (Mako), Zimmer Biomet (ROSA), and Smith & Nephew (CORI).
- Patient-Specific Knee Implants: Custom-designed knee implants using 3D printing. Market share data unavailable. Competitors include Conformis (CFMS) and larger orthopedic companies offering custom solutions.
Market Dynamics
Industry Overview
The orthopedic implant market is a large and growing market, driven by an aging population, increasing obesity rates, and advancements in surgical techniques and materials.
Positioning
Monogram Orthopaedics is positioned as an innovator in the orthopedic market, focusing on personalized solutions and robotic surgery. Its competitive advantage lies in its patient-specific approach and advanced technology.
Total Addressable Market (TAM)
The total addressable market for orthopedic implants is estimated to be in the tens of billions of dollars. Monogram Orthopaedics is targeting a segment of this market with its personalized implants and robotic surgery system. The TAM for personalized implants and robotic-assisted surgery is growing rapidly and is expected to continue to grow in the coming years. Monogram is positioned to capture a meaningful share of this growing market
Upturn SWOT Analysis
Strengths
- Innovative technology platform
- Patient-specific solutions
- Strong intellectual property portfolio
- Experienced leadership team
Weaknesses
- Limited commercialization experience
- High R&D expenses
- Dependence on regulatory approvals
- Small market share relative to competitors
Opportunities
- Expanding robotic surgery market
- Growing demand for personalized implants
- Strategic partnerships with hospitals and surgeons
- Potential for international expansion
Threats
- Competition from established orthopedic companies
- Reimbursement challenges
- Technological obsolescence
- Economic downturn
Competitors and Market Share
Key Competitors
- Stryker (SYK)
- Zimmer Biomet (ZBH)
- Smith & Nephew (SNN)
- Conformis (CFMS)
Competitive Landscape
Monogram Orthopaedics faces intense competition from larger, well-established orthopedic companies. Its advantages lie in its patient-specific approach and robotic technology, but it must overcome its limited commercial experience and financial resources.
Growth Trajectory and Initiatives
Historical Growth: Monogram Orthopaedics' historical growth has been characterized by significant R&D investment and development of its technology platform, but the company has minimal revenues.
Future Projections: Future growth projections are heavily dependent on regulatory approvals, successful commercialization of its robotic system and implants, and its ability to secure financing. Analyst estimates vary widely due to the company's stage of development.
Recent Initiatives: Recent initiatives include advancing its robotic surgical system towards commercial launch, expanding its patent portfolio, and engaging with surgeons and hospitals to drive adoption of its technology.
Summary
Monogram Orthopaedics is an early-stage company with innovative technology in the orthopedic space, focusing on personalized implants and robotic surgery. Its strengths include its technology and intellectual property, but it faces challenges related to commercialization, competition, and regulatory approvals. The company's success hinges on its ability to navigate these challenges and establish a foothold in the market. Investors should monitor closely its progress toward commercialization and adoption of its robotic surgery system.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings (SEC)
- Company investor presentations
- Analyst reports (where available)
- Industry reports (e.g., orthopedic market research)
- Company website
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. The information provided is based on publicly available data and may not be entirely accurate or complete. Investment decisions should be made based on individual circumstances and after consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Monogram Orthopaedics Inc. Common Stock
Exchange NASDAQ | Headquaters Austin, TX, United States | ||
IPO Launch date 2023-05-18 | Chairman of the Board, President & CEO Mr. Benjamin Sexson C.F.A. | ||
Sector Healthcare | Industry Medical Devices | Full time employees 27 | |
Full time employees 27 | |||
Monogram Technologies Inc. engages in developing surgical robot to enable placement of patient optimized orthopedic implants in the United States. It intends to produce and market robotic surgical equipment and related software, orthopedic implants, tissue ablation tools, navigation consumables, and other miscellaneous instrumentation for use in reconstructive joint replacement procedures. The company was formerly known as Monogram Orthopaedics, Inc. and changed its name to Monogram Technologies Inc. in May 2024. Monogram Technologies Inc. was founded in 2015 and is headquartered in Austin, Texas.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.